ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2013, Vol. 22 ›› Issue (4): 315-323.

• 论文 • 上一篇    下一篇

尿液microRNAs作为局灶节段性肾小球硬化疾病活动生物标志物的研究

  

  • 出版日期:2013-08-28 发布日期:2013-09-03

Urinary microRNAs are the biomarker for the disease activity of patients with focal segmental glomerulosclerosis

  • Online:2013-08-28 Published:2013-09-03

摘要:

摘  要  目的:研究局灶节段性肾小球硬化(FSGS)患者尿液中microRNAs的表达变化以及miRNAs的变化与FSGS患者疾病活动性之间的关系。方法:检测尿液miRNAs的表达谱,及其在活动性FSGS患者,非活动性FSGS患者和正常对照尿液中的水平,分析尿液中miRNAs的表达变化与尿蛋白、白蛋白等临床指标之间的关系。并与膜性肾病及糖尿病肾病患者尿液miRNAs水平进行比较,评判特异性。结果:活动性FSGS组尿液miR-196a,miR-30a,miR-155和miR-490的表达水平不仅显著高于正常对照组而且高于非活动性FSGS组(P<0.001)。尿液miR-196a,miR-155,miR-30a和miR-490的变化倍数与FSGS患者的尿蛋白、血白蛋白、血清总胆固醇存在显著相关性(P<0.05)。在膜性肾病和糖尿病肾病患者尿液中没有观察到上述变化。激素治疗有效的FSGS患者的尿液中,miR-196a,miR-490,miR-30a表达水平随着病情的缓解也明显下降(P<0.05)。激素治疗无效患者的尿液中,miRNAs表达水平治疗前后没有显著差异(P>0.05)。结论:尿液miR-196a,miR-30a和miR-490表达水平与FSGS患者疾病的活动性密切相关,提示尿液miR-196a,miR-30a和miR-490检测有可能作为判断FSGS疾病活动性和反应疗效的新的生物标志物。

关键词: 关键词:局灶节段性肾小球硬化  , 尿液microRNAs  , 生物标志物

Abstract:

Abstract   Objective: To examined the microRNA expression profile of urine supernatant in patients with focal segmental glomerulosclerosis (FSGS) and analyze the correlation between the level of miRNAs and the activity of disease. Methodology: Urine supernatant samples from patients with active FSGS (urinary protein excretion ≥3.5g/24h), non-active FSGS (urinary protein excretion ≤0.4g/24h) and normal controls were tested by quantitative Real-time PCR. The correlation between the urinary miRNAs expression levels and clinical indexes were analyzed. In order to evaluate the specificity, urinary miRNAs level of patients with membranous nephropathy (MN) and diabetic nephropathy (DN) was also detected for validation. Results: The urinary expression levels of miR-196a, miR-30a, miR-155 and miR-490 were significantly elevated in active FSGS compared to the non-active FSGS patients and normal control (P<0.001). The expression level of miR-196a, miR-30a, miR-155 and miR-490 was correlated with clinical indexes, such as proteinuria and serum albumin level (P<0.05). However, the same change of miR-196a, miR-30a and miR-490 was not found in the urine of MN and DN patients. Conclusion: Urinary expression level of miR-196a, miR-30a and miR-490 correlated with disease activity suggested that miR-196a, miR-30a and miR-490 might be the new urinary biomarker for disease activity and therapeutic effects of FSGS.

Key words: KEY WORDS:FSGS     ,  urinary microRNAs    , biomarker.